Preliminary study results suggest pregnant women who received the tetanus-diphtheria-acellular pertussis (Tdap) vaccine were not at increased risk for adverse maternal or birth outcomes.

In 2012, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended that all women, regardless of vaccination status, receive the Tdap vaccine during pregnancy. According to the ACIP, pregnant women should receive the vaccine between 27 and 36 weeks gestation, which has been identified as the optimal time to maximize the transfer of antibodies from mother to child.